Progress and problems in the diagnosis and treatment of immune checkpoint inhibitor related liver injury in cancer
10.3781/j.issn.1000-7431.2024.2305-0246
- VernacularTitle:肿瘤免疫检查点抑制剂治疗相关性肝损伤诊疗进展及存在的问题
- Author:
Kaifeng WANG
1
;
Zhongzhong PENG
;
Xikai ZHANG
;
Xiao ZHOU
;
Xianyuan MIAO
;
Qiongqiong WANG
;
Sijia REN
;
Baiwen ZHANG
;
Yi WANG
;
Yue MA
Author Information
1. 上海交通大学医学院附属仁济医院肿瘤科,上海 200127
- Keywords:
Malignant tumors;
Immune checkpoint inhibitor;
Liver injury;
Immune-mediated liver injury caused by ICIs
- From:
Tumor
2024;44(1):89-100
- CountryChina
- Language:Chinese
-
Abstract:
The immune related adverse events(irAE)caused by tumor immune checkpoint inhibitors(ICI)have attracted increasing attention of clinical experts.Immune-mediated liver injury caused by ICIs(ILICI)is not uncommon in clinical practice,but specific diagnostic method of ILICI is lacking.Biopsy of liver tissue can help improve the diagnosis and management of ILICI.In the treatment of ILICI,the immediate use of corticosteroid therapy is not necessarily.A balance between efficacy,toxicity,and specific treatment need to be achieved,and further refined through multidisciplinary team(MDT)cooperation.Appropriate dosaging and identification of novel predictive targets should be considered in order to reduce the incidence and severity of ILICI in the future.Meanwhile,further basic research is required to elucidate the potential pathophysiological mechanisms and risk factors of ILICI.With the refinement of evidence in clinical evidence-based medicine and deepening of basic research,the diagnosis and treatment level of ILICI will also be further improved.
